|Articles|August 22, 2016
Bioclinica Enters Agreement to be Acquired by Cinven
Bioclinica has signed an agreement to be acquired by international private equity firm Cinven.
Advertisement
Bioclinica has signed an agreement to be acquired by international private equity firm Cinven. The Pennsylvania-based clinical trial technology and services company, which this year reorganized into three core business segments, will mark the first investment from the Sixth Cinven Fund, which is targeting assets that can strategically drive growth in Europe and globally.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5